About Us

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes.

Our focus is on developing and commercializing effective new diagnostic and therapeutic radiopharmaceuticals for metastatic cancer. Using the radioisotope fluorine-18 (atomic number 9) we can precisely image cancers and determine if they have metastasized. Guided by PET imaging to see a patient’s cancer, the same molecules can be used to treat it.

By attaching a therapeutic radioisotope such as Actinium-225 (an alpha emitter) we selectively treat each cancer site, while sparing normal organs, to improve the outcome of cancer patients. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the life of patients affected by metastatic cancers.

“What’s In A Name”

“Alpha-9” combines our approach of using superior Alpha emitters for therapy, with “9” the atomic number for fluorine, the choice isotope for PET imaging made possible with our “boron-tag” technology.

Platform Technology

We are applying our proprietary technologies to design molecules that harness the power of radioactivity to better image and directly deliver radiotherapy to cancer cells. We combine powerful, non-invasive, positron emission tomographic (PET) imaging with targeted radiotherapy for precision cancer treatments. By using imaging to "see" a patient's cancer, we use the same approach to precisely deliver therapeutic radioisotopes to tumour sites.

Our Know-how

Our scientific founders are leaders in nuclear medicine, radiochemistry, and synthetic chemistry with over 60 years combined experience in the design of new radiotheranostics. With this multidisciplinary know-how, we are bringing forward novel products for cancer imaging and treatment.

Breakthrough Products

We have developed new breakthrough technology for improved imaging and therapy. Our "boron-tag" chemistry significantly expands PET imaging, enabling any molecule to become an imaging agent. Beyond improved diagnosis, we are using imaging to guide the design of agents that deliver therapeutic radionuclides.

Latest News & Developments

Successful Completion of Phase I/II Trial with A9T-1101

NEWS RELEASE   Alpha-9 Theranostics Announces Successful Completion of Phase I/II Trial with A9T-1101 in patients with Neuroendocrine Tumours  Diagnostic Imaging Candidate  Confirms Utility of BF3...

October 30, 2020

First Patient Dosed With A9T-1101

NEWS RELEASE First Patient Dosed with A9T-1101. First Product Candidate in Alpha-9 Theranostics Pipeline  Initiates Clinical Testing.  Vancouver, Canada:  June 16th, 2020 Alpha-9 Theranostics In...

June 16, 2020

Board members appointed

Alpha9 Theranostics appoints Simon Pimstone & Michael Reitermann to Board of Directors Vancouver, Canada: Alpha9 Theranostics Inc. today announced that it has appointed two senior independent Non-...

May 15, 2020